Core Illumina revenue of $1.04 billion for Q1 2025, down 1% from Q1 2024 (flat on a constant currency basis) GAAP operating margin...
Shuttle Pharmaceuticals Holdings, Inc. , a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer pati...
ANPD001 was well tolerated with no major safety issues in low-dose cohort Patients showed early improvements in patient-reported and clinician-re...
- Patients treated with VCN-01 (zabilugene almadenorepvec) plus standard gemcitabine/nab-paclitaxel chemotherapy had increased overall survival, progress...
GeneFab, a next-generation cell and gene therapy-focused contract research, development, and manufacturing organization (CRDMO), has partnered with RegCe...
600-patient study to assess efficacy of rhu-pGSN, an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance of pa...
Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfoli...
The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentat...
Roquette, a global leader in plant-based ingredients and pharmaceutical excipients for the health and nutrition sectors, announces today a new organizati...
In the Phase 2 open-label study, REC-4881 (4 mg QD) led to a median 43% reduction (n=6 patients) in polyp burden at the Week 13 assessment at time of d...
Scorpius Holdings, Inc. (OTC: SCPX), a biomanufacturing company dedicated to advancing therapeutic production capabilities, today announced a comprehensi...
Delivered total first quarter revenue of $707 million, an increase of 11% on a reported and core revenue basis, including Screening revenue of ...
Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corp...
Along with PCI’s own robust infrastructure expansions, acquisition furthers CDMO’s recent growth in sterile fill-finish, advanced drug delivery...
© 2025 Biopharma Boardroom. All Rights Reserved.
